Nuplazid (pimavanserin) is a small molecule pharmaceutical. Pimavanserin was first approved as Nuplazid on 2016-04-29. It is used to treat hallucinations, parkinson disease, and schizophrenia spectrum and other psychotic disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A. Nuplazid's patents are valid until 2038-08-27 (FDA).
|Indication||hallucinations, parkinson disease, schizophrenia spectrum and other psychotic disorders|
|Drug Class||Serotonin 5-HT2 receptor antagonists|